Brivaracetam latest market price reference instructions

Brivaracetam/Brivaracetam (Brivaracetam), trade nameBriviact, has been on the market for many years in Europe, the United States, Japan and other countries, and is one of the important drugs for the treatment of epilepsy. Its R&D company is UCB Pharmaceuticals of Belgium, which is also the original manufacturer of Levetiracetam. As its successor product, Brivaracetam has significant improvements in efficacy, metabolism and tolerability.

At present, the original drug of Brivaracetam has not been officially launched in mainland China, so domestic pharmacies and hospitals are temporarily unable to purchase the original drug, and there is no news of approval. According to overseas drug market information, the market price of the European version of Brivaracetam 50mg Some regional pharmacies offer 100mg strength at a slightly higher price. The drug is relatively more expensive in the United States, costing more than $700 per month.

Since there are no domestic sales channels, some patients will choose to purchase drugs through regular overseas pharmacies or international medical platforms. However, they need to pay attention to the legality of the source of the drugs and the quality assurance of the transportation process. At the same time, Brivaracetam is a strictly prescribed drug, and its cross-border purchases should be made after a doctor issues a prescription to ensure the safety of the drug.

It is worth mentioning that some pharmaceutical companies have announced plans to promote brivaracetam generic drugs or cooperative introduction projects in the Asian market. Once approved, it will significantly reduce prices and increase accessibility. In the future, as domestic drug registration and approval speeds up, Brivaracetam is expected to enter the Chinese market in the next two to three years and be included in the national medical insurance system, thus reducing the burden on patients.

Overall, the price of this drug is relatively high, but its stability and safety have been widely verified in international clinical use, and it is still an important drug choice for the long-term control of epilepsy.

Reference materials:https://www.briviact.com/